Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

Trial Profile

A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berubicin (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; First in man
  • Sponsors WPD Pharmaceuticals

Most Recent Events

  • 03 Jun 2024 Planned End Date changed from 1 Dec 2025 to 30 Dec 2023.
  • 03 Jun 2024 Planned primary completion date changed from 1 Dec 2025 to 30 Dec 2023.
  • 03 Jun 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Business decision)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top